Cross Country 2025 Q2 Earnings Narrowed Losses as Net Loss Drops 58.5%
Generado por agente de IAAinvest Earnings Report Digest
jueves, 7 de agosto de 2025, 4:55 pm ET1 min de lectura
CCRN--
Cross Country Healthcare reported its Q2 2025 earnings on August 7, 2025. The results were in line with expectations, showing a reduction in losses. The company narrowed its net loss to $6.66 million, or $0.20 per share, compared to $16.05 million, or $0.47 per share, a year earlier, representing a 58.5% improvement. No updated guidance was provided.
Revenue
Cross Country’s total revenue for the second quarter of 2025 declined by 19.3% to $274.07 million from $339.77 million in the prior-year period. The company’s nurse and allied staffing segment generated $224.31 million, reflecting a 23% year-over-year decline, while physician staffing revenue rose 3% to $49.77 million. The sequential drop in overall revenue of 7% was driven by a 7% decline in nurse and allied staffing and a 3% decrease in physician staffing. The nurse and allied segment also saw a 7% sequential reduction, with the physician staffing segment experiencing a modest 3% year-over-year growth due to favorable pricing and mix.
Earnings/Net Income
The company significantly reduced its net loss to $-6.66 million, or $-0.20 per share in 2025 Q2, from $-16.05 million, or $-0.47 per share in the same period of 2024, representing a 58.5% improvement. This marked a positive shift in the company's financial performance, indicating better cost control and operational efficiencies.
Price Action
Cross Country's stock experienced a 2.75% increase on the latest trading day but dipped 0.23% over the past week. The stock was up 2.75% month-to-date, reflecting a mixed investor sentiment post-earnings.
Post-Earnings Price Action Review
A strategy of buying CCRNCCRN-- shares when earnings exceeded expectations and selling after 30 days delivered a 128.53% return, far surpassing the benchmark's 78.57% gain. The strategy demonstrated strong risk management, with a maximum drawdown of 0.00% and a Sharpe ratio of 0.42, highlighting its appeal for investors seeking balanced returns and stability.
Additional News
On August 7, 2025, Cross CountryCCRN-- Healthcare announced its second-quarter financial results, with a pending merger with Aya Healthcare expected to close in Q4 2025. The merger has drawn significant attention from investors and analysts. The company did not host an earnings call due to the pending transaction, nor did it provide forward-looking guidance. Additionally, Cross Country's balance sheet remains robust, with $81.2 million in cash and no debt as of June 30, 2025. The company reported a 5% sequential decline in SG&A expenses, attributed to cost savings from its low-cost center of excellence in India.
Revenue
Cross Country’s total revenue for the second quarter of 2025 declined by 19.3% to $274.07 million from $339.77 million in the prior-year period. The company’s nurse and allied staffing segment generated $224.31 million, reflecting a 23% year-over-year decline, while physician staffing revenue rose 3% to $49.77 million. The sequential drop in overall revenue of 7% was driven by a 7% decline in nurse and allied staffing and a 3% decrease in physician staffing. The nurse and allied segment also saw a 7% sequential reduction, with the physician staffing segment experiencing a modest 3% year-over-year growth due to favorable pricing and mix.
Earnings/Net Income
The company significantly reduced its net loss to $-6.66 million, or $-0.20 per share in 2025 Q2, from $-16.05 million, or $-0.47 per share in the same period of 2024, representing a 58.5% improvement. This marked a positive shift in the company's financial performance, indicating better cost control and operational efficiencies.
Price Action
Cross Country's stock experienced a 2.75% increase on the latest trading day but dipped 0.23% over the past week. The stock was up 2.75% month-to-date, reflecting a mixed investor sentiment post-earnings.
Post-Earnings Price Action Review
A strategy of buying CCRNCCRN-- shares when earnings exceeded expectations and selling after 30 days delivered a 128.53% return, far surpassing the benchmark's 78.57% gain. The strategy demonstrated strong risk management, with a maximum drawdown of 0.00% and a Sharpe ratio of 0.42, highlighting its appeal for investors seeking balanced returns and stability.
Additional News
On August 7, 2025, Cross CountryCCRN-- Healthcare announced its second-quarter financial results, with a pending merger with Aya Healthcare expected to close in Q4 2025. The merger has drawn significant attention from investors and analysts. The company did not host an earnings call due to the pending transaction, nor did it provide forward-looking guidance. Additionally, Cross Country's balance sheet remains robust, with $81.2 million in cash and no debt as of June 30, 2025. The company reported a 5% sequential decline in SG&A expenses, attributed to cost savings from its low-cost center of excellence in India.

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios